tag:blogger.com,1999:blog-7857054149675424609.post1901387616416303528..comments2024-02-24T08:58:08.581+00:00Comments on RNAi Therapeutics: RNAi Therapeutics is Dead, Long Live RNAi TherapeuticsDirk Hausseckerhttp://www.blogger.com/profile/18320439857875629714noreply@blogger.comBlogger13125tag:blogger.com,1999:blog-7857054149675424609.post-18320611674105755552011-03-26T11:49:23.855+00:002011-03-26T11:49:23.855+00:00p10 of the Viriathus Overview report for Benitec u...p10 of the Viriathus Overview report for Benitec under Dirk's google news rnai links.Anonymousnoreply@blogger.comtag:blogger.com,1999:blog-7857054149675424609.post-39018870524118259692011-03-26T02:48:18.712+00:002011-03-26T02:48:18.712+00:00Anonymous, "Pfizer have decided to continue w...Anonymous, "Pfizer have decided to continue with their HCV Rnai effort." <br /><br />Whilst I certainly hope this is the case, I have been unable to verify this. Would you mind posting a link? Thanks in advance.<br /><br />Keep up the good work Dirk. Cheers from Downunder.Gene Genienoreply@blogger.comtag:blogger.com,1999:blog-7857054149675424609.post-31540992669466757692011-03-25T01:52:03.265+00:002011-03-25T01:52:03.265+00:00In the last week city of hope announce new stage o...In the last week city of hope announce new stage of HIV Rnai trial, and also Pfizer have decided to continue with their HCV Rnai effort. I think the journos writing these 'rnai is over' articles are a bit lazyAnonymousnoreply@blogger.comtag:blogger.com,1999:blog-7857054149675424609.post-31041628914196884532011-02-26T01:25:04.751+00:002011-02-26T01:25:04.751+00:00First of all, thanks for your continued, measured,...First of all, thanks for your continued, measured, intelligent blog.<br /><br />Secondly, the cycle of boom, over-investment, bust and recovery to greater heights is a common dynamic in financial systems. It happened in video games, computers, software, Internet communications. It is now happening in RNA chemistry!<br /><br />The trick is to understand, with BigPharma, we are effectively Enumeratenoreply@blogger.comtag:blogger.com,1999:blog-7857054149675424609.post-83225918678652055112011-02-25T08:31:58.503+00:002011-02-25T08:31:58.503+00:00Mike: Thanks for the ROSG update. A number of pure...Mike: Thanks for the ROSG update. A number of pure-play RNAi companies would benefit from having such activist investors. In the case of ROSG, I would hope that they shake things up at the commercial end of the business, focusing on the 'production' and distribution of the mirView Mets tests. <br /><br />BTW, some of the pure-play RNAi companies are getting so small that it might also Dirk Hausseckerhttps://www.blogger.com/profile/18320439857875629714noreply@blogger.comtag:blogger.com,1999:blog-7857054149675424609.post-31985621639142655912011-02-24T23:11:16.047+00:002011-02-24T23:11:16.047+00:00Dirk,
I know you have followed Rosetta Genomics f...Dirk,<br /><br />I know you have followed Rosetta Genomics for a while. Like you, I have viewed them as having good science all the while being terribly mismanaged as a company. Becker & Drapkin (actvist investors) reported a large stake in them after the bell (it is on the ROSG website). Just google Becker & Drapkin and you will see they like to shake things up at companies they invest Mikenoreply@blogger.comtag:blogger.com,1999:blog-7857054149675424609.post-21952823403465098082011-02-23T19:32:08.671+00:002011-02-23T19:32:08.671+00:00Sure, why not let most of the biotech industry die...Sure, why not let most of the biotech industry die? It's not a secret that drug development is a long relay and it is easy to put pressure on the early-stage companies without immediately feeling the repercussions at the end. When the overall healthcare sector was in better shape, it was an era where companies made deals that fairly shared risk and reward. Today is vulture capitalism gone Dirk Hausseckerhttps://www.blogger.com/profile/18320439857875629714noreply@blogger.comtag:blogger.com,1999:blog-7857054149675424609.post-83047741675995101072011-02-23T04:47:01.164+00:002011-02-23T04:47:01.164+00:00Playing devil's advocate: Why shouldn't ph...Playing devil's advocate: Why shouldn't pharma let pure-play RNAi companies do the heavy lifting? The pharma companies that have invested early in RNAi have precious little to show for it, so far. Why not let Alnylam/Tekmira/Silence prove out RNAi in the clinic before investing? By the time pure-play RNAi companies are done with the dilutive financings necessary to develop their pipelinesAnonymousnoreply@blogger.comtag:blogger.com,1999:blog-7857054149675424609.post-85158808626153948982011-02-22T13:46:21.305+00:002011-02-22T13:46:21.305+00:00SO what have you done about it Dirk if it all didn...SO what have you done about it Dirk if it all didnt make sense to you. this is how they control the market and stock prices. It looks like your blog aint going to cut it. but maybe thats a good thing while us bottom feeders accumulate at these low prices : ) GOOOOOO BENITEC I SAY MATE.. WE WILL SHOCK YOU !!!Anonymousnoreply@blogger.comtag:blogger.com,1999:blog-7857054149675424609.post-85092697912155572842011-02-21T21:19:18.392+00:002011-02-21T21:19:18.392+00:00Private Investors: I'm afraid that only few pu...Private Investors: I'm afraid that only few pure-play companies care somewhat about their investment success. Something the field need to improve upon. <br /><br />The New York Times article: No disrespect to the author, but I was shocked by what effect such an article could have, even though there was really no new information or special insight in there. It's fair for the general publicDirk Hausseckerhttps://www.blogger.com/profile/18320439857875629714noreply@blogger.comtag:blogger.com,1999:blog-7857054149675424609.post-79160018745136626962011-02-21T21:04:09.894+00:002011-02-21T21:04:09.894+00:00Dirk:
You didn't mention Calando's succes...Dirk:<br /><br />You didn't mention Calando's success with its delivery system. Do you consider it to be an important addition to the expanding list of viable technologies?Anonymousnoreply@blogger.comtag:blogger.com,1999:blog-7857054149675424609.post-30088400926034775662011-02-21T20:59:05.021+00:002011-02-21T20:59:05.021+00:00I must admit that an article in the New York Times...I must admit that an article in the New York Times last week induced me to sell my stake in Alnylam out of fear that it would continue to decline. I have since bought back %50 but at a higher price. Funny thing is, you couldn't twist my arm hard enough to sell when it was up to $37.Anonymousnoreply@blogger.comtag:blogger.com,1999:blog-7857054149675424609.post-39426212456270402752011-02-21T19:35:16.871+00:002011-02-21T19:35:16.871+00:00Too true Dirk and it's all been very 'test...Too true Dirk and it's all been very 'testing' for private investors!Anonymousnoreply@blogger.com